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Abstract
Background: Recent studies emphasise the importance of timely diagnosis and early initiation of
disease-modifying treatment in the long-term prognosis of multiple sclerosis.
Objectives: The objective of this study was to investigate factors associated with extended time to
diagnosis and time to disease-modifying treatment initiation in the Swiss Multiple Sclerosis Registry.
Methods: We used retrospective data (diagnoses 1996–2017) of the survey-based Swiss Multiple
Sclerosis Registry and fitted logistic regression models (extended time to diagnosis 2 years from
first symptoms, extended time to disease-modifying treatment initiation 1 year from diagnosis) with
demographic and a priori defined variables.
Results: Our study, based on 996 persons with multiple sclerosis, suggests that 40% had an extended
time to diagnosis, and extended time to disease-modifying treatment initiation was seen in 23%. Factors
associated with extended time to diagnosis were primary progressive multiple sclerosis (odds ratio (OR)
5.09 (3.12–8.49)), diagnosis setting outside of hospital (neurologist (private practice) OR 1.54 (1.16–
2.05)) and more uncommon first symptoms (per additional symptom OR 1.17 (1.06–1.30)). Older age at
onset (per additional 5 years OR 0.84 (0.78–0.90)) and gait problems (OR 0.65 (0.47–0.89)) or pares-
thesia (OR 0.72 (0.54–0.95)) as first symptoms were associated with shorter time to diagnosis. Extended
time to disease-modifying treatment initiation was associated with older age at diagnosis (per additional
5 years OR 1.18 (1.09–1.29)). In more recent years, time to diagnosis and time to disease-modifying
treatment initiation tended to be shorter.
Conclusions: Even in recent periods, substantial and partially systematic variation regarding time to
diagnosis and time to disease-modifying treatment initiation remains. With the emerging paradigm of
early treatment, the residual variation should be monitored carefully.
Keywords: Registries, logistic models, disease-modifying treatment, retrospective studies, age of onset,
time to diagnosis
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Introduction
The management of multiple sclerosis (MS) is evolv-
ing with revised diagnostic criteria and new treat-
ments based on different targeting strategies
approved in recent years or in the pipeline, mainly
for relapsing–remitting multiple sclerosis (RRMS).1–5
In addition, first treatments that show clinical benefits
in progressive disease stages (primary-progressive
multiple sclerosis (PPMS) and secondary-
progressive multiple sclerosis (SPMS)) are emerg-
ing.2,4,5 However, the risk–benefit assessment of
treatments as well as the overall therapeutic decisions
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are gaining in complexity.6,7 The way the disease is
diagnosed and managed is frequently adapted to the
most recent evidence to provide optimal treatment
and care.1
An expert panel recently identified a timely diagno-
sis and treatment initiation as the most influential
factors for disease control and an increased likeli-
hood of a milder disease course.8 The rationale
behind this approach is to limit inflammatory and
possibly degenerative damage to the brain tissue.
Indeed, evidence suggests that for RRMS this early
treatment approach seems to reduce disease progres-
sion and the conversion rate to SPMS.9–11
Recent studies found that time to diagnosis in MS
was reduced over time, but may still be substan-
tial.12,13 In part, the variation in time to diagnosis
may be systematic, as exemplified by a Canadian
study that identified younger age at onset and
PPMS as factors associated with referral delays.14
But overall, the relevance of other factors such as
first symptoms and the diagnostic setting
remains elusive.
The aim of this study was to investigate driving
factors associated with extended intervals between
first symptoms and definite MS diagnosis as well
as factors associated with extended intervals
between diagnosis and disease-modifying treatment
(DMT) initiation. We therefore intended to identify
factors of relevance regarding early diagnosis and
management of MS and potential bottlenecks in
the healthcare system that could be addressed in
the future.
Methods
Study population
For the present study, we analysed data of 1059
participants of the Swiss Multiple Sclerosis
Registry (SMSR) who were diagnosed with MS
after 1995 (introduction of the first DMT in
August 1995 in Switzerland, (interferon beta-1b
(Betaferon))) and having clinically definite MS
(Figure 1).15,16
Study design
We used data of the SMSR, which is a prospective,
observational, patient-centred, ongoing study includ-
ing adult persons with MS (PwMS) living in
Switzerland. This innovative study obtains data
directly from PwMS by online and paper question-
naires but includes clinical data collection with the
treating physicians for validation purposes. Between
the launch of the SMSR in June 2016 and 1
November 2017, the SMSR has collected 1365 ini-
tial questionnaires. Participants are asked to submit a
diagnosis confirmation signed by their treating phy-
sician to ascertain the disease status. This diagnosis
confirmation is a requirement for persons to enter
the regular follow-up surveys. The registry is a rep-
resentative sample of the adult Swiss MS population,
with a coverage of at least 12%. The study was
approved by the ethics committee of the canton of
Zurich (PB-2016-00894) and written informed con-
sent was obtained from all SMSR participants.17,18
Outcome measures
We looked at two different outcomes. The first out-
come was the time between the first symptoms and
the definitive diagnosis of MS (time to diagnosis).
This outcome was available for 996 PwMS of whom
990 had no missing values in the covariates and were
therefore included in the analysis (Figure 1). For the
purpose of interpretability, the interval was dicho-
tomised into less than 2 and 2 or more years, with
the latter henceforth being referred to as extended
time to diagnosis. The cut-off of 2 years was deter-
mined a priori based on the expertise of two neurol-
ogists and not according to the available data.
The second outcome concerned the time between
diagnosis and first DMT (time to DMT initiation).
This outcome was only defined for PwMS with a
relapsing-onset disease and a diagnosis before the
year 2017 (Figure 1), with a final sample size of
872. In this analysis, time to DMT initiation was
also dichotomised for better interpretability, using
1 year as a cut-off (i.e. time <1 or 1 year) accord-
ing to the advice of two neurologists.
Identification of factors potentially associated with
time to diagnosis and time to treatment
We used a fixed and a variable set of factors, both of
which were determined a priori. The fixed set
included in all models was identified by literature
search as either being associated with time to diag-
nosis and time to DMT initiation or being demo-
graphic variables commonly used.
The following factors were included in the fixed set:
disease course (relapsing-onset MS (reference level),
PPMS), age at onset, year of diagnosis (5-year peri-
ods from 1996 to 2017 (1996–2000 is reference
level)) and sex (female (reference level), male).14
Furthermore, we identified a pool of potential fac-
tors, which were included in the models on the basis
of statistical criteria (variable set). For the time to
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diagnosis outcome, the variable set consisted of the
following self-reported MS symptoms occurring at
the first manifestation of the disease (based on a
standardised set as used, for example, by the
German MS Registry and evaluated by experts):19
visual disturbances; speech, swallowing, gait, bal-
ance, bladder, bowel and memory problems; weak-
ness; paralysis; fatigue; paresthesia; dizziness;
pain; spasms; tics; tremor; epilepsy; sexual dys-
function or depression (absence is reference
level). The number of first symptoms, the number
of common (based on occurrence frequencies in
the SMSR (20%) (paraesthesia, visual disturban-
ces, fatigue, gait problems, weakness, balance
problems, paralysis and dizziness/vertigo)
(Supplementary Table 1) and uncommon first
symptoms (the remainder), the typology of the cur-
rent home residence (urban (reference level), urban
to rural, rural), if the home residence is located in a
mountainous area (not mountainous (reference
level), mountainous), defined as living in one of
the ‘Gebirgskantone’ (Uri, Obwalden, Nidwalden,
Glarus, Graubu¨nden, Tessin and Wallis), in the
canton of Jura or the Bernese ‘Oberland’, language
area of Switzerland (German (reference level),
French, Italian), having Swiss citizenship (yes (ref-
erence level), no) and the setting of the diagnosis
(neurologist in hospital (reference level), neurolo-
gist in private practice, general practitioner) were
the other variables. The factors for the time to
DMT initiation were identical except for disease
course, due to the existing prescription guidelines
and first symptoms, in which a mix of the effect of
first symptoms and symptoms at diagnosis can cur-
rently not be disentangled.
Statistical analysis
We fitted logistic regression models for both out-
comes using the variables of the fixed set and
extended the model by including factors from the
variable set on the basis of the Akaike information
criterion (AIC) in a bottom-up variable selection
Figure 1. Flow chart showing study population. The first set concerns the time between the first symptoms and diagnosis (1365 to 990) (column 2
in Table 1). The second set is the time between diagnosis and disease-modifying treatment start (1059 to 872) (column 3 in Table 1). CDMS:
clinically definite multiple sclerosis.
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approach.20 This approach was chosen to incorporate
the prior evidence as well as to consider the large
number of potential covariates while preventing
overfitting. We coded an algorithm that added –
one at a time – the potential variables and fitted
each of the corresponding models. Then the AICs
of the models were compared and the one with the
lowest value was chosen. If this AIC was at least
2 units smaller than the AIC of the previous refer-
ence model, the corresponding model was defined as
the new reference model. The added variable was
consequently removed from the variable set and
the procedure started anew. It was repeated until
none of the remaining variables could further
improve the model fit.21,22
The time to diagnosis model was refit using the
information of the physician-signed diagnosis con-
firmation as a sensitivity analysis. To this end, the
self-reported MS type, date of diagnosis and setting
of the diagnosis were replaced by physician-reported
information of the diagnosis confirmation (sample
size 704). Furthermore, the time to diagnosis
model was refit on a restricted dataset (diagnoses
2006–2015 (sample size 567)) as a sensitivity anal-
ysis for the healthy survivor bias. For the time to
DMT initiation model the sensitivity analysis con-
sisted of refitting the model on a dataset restricted to
PwMS with a time to DMT initiation within
12 months and a cut-off of 3 months was chosen
(sample size 585).
All statistical analyses were performed using R, ver-
sion 3.3.3.23
Results
Population characteristics
The characteristics of our study population and the
analysis datasets at the time of enrolment into the
SMSR (during years 2016 and 2017) are displayed in
Table 1. The most common type of disease course is
RRMS (76%), followed by SPMS (14%) and PPMS
(10%). The sex ratio is 2.7:1 (female to male), the
median age 47 years (interquartile range (IQR)
38–55) and the median disease duration is 9 years
(IQR 4–14). The median age at diagnosis is 38 years
(IQR 29–45) (corresponding distribution shown in
Supplementary Figure 1). The percentage of PwMS
with Swiss citizenship is 91%.
Factors associated with extended time to diagnosis
The time to diagnosis is displayed in Figure 2. The
curve has a steep increase, with 50% being
diagnosed within 1.1 years and 60% after no more
than 2 years (range 0–52 years). However, 13% also
had a time to diagnosis of at least 10 years. The
distribution of the population characteristics split
by less than 2 (60%) compared to 2 or more years
(40%) until diagnosis is displayed in Supplementary
Table 2.
The results of the time to diagnosis model are shown
in Figure 3 (numbers see Supplementary Table 3).
The strongest factors for extended time to diagnosis
was having PPMS (odds ratio (OR) 5.09 (3.12–
8.49)). Being diagnosed by a neurologist in a private
practice as opposed to in a hospital (1.54 (1.16–
2.05)) and having a higher number of uncommon
first symptoms (1.17 (1.06–1.30) per additional
symptom) were also associated with an extended
time to diagnosis.
By contrast, older age at onset (0.84 (0.78–0.90) per
age increase of 5 years) or having either of two
common first symptoms (gait problems (0.65
(0.47–0.89)), paresthesia (0.72 (0.54–0.95))) were
associated with shorter time to diagnosis.
Furthermore, the time to diagnosis tended to be
extended for diagnoses between 1996 and 2000
and to become gradually shorter afterwards (1996–
2000 1, 2001–2005 0.83 (0.52–1.31), 2006–2010
0.92 (0.60–1.40), 2011–2015 0.77 (0.51–1.15),
2016–2017 0.55 (0.31–0.95)).
The sensitivity analyses performed agreed well with
the previous model (Supplementary Tables 3–5).
Factors associated with extended time to
DMT initiation
Figure 4 shows the time to DMT initiation. Similar
to the time to diagnosis curve, it has a steep increase.
Over 50% of the eligible PwMS started DMT within
2 months after diagnosis, 77% within 1 year (range
0–20 years). Nevertheless, 23% initiated therapy
only after 1 year or not at all (n=72, 8%). The dis-
tribution of the population characteristics split by
less than 1 (77%) compared to 1 or more years
(23%) until time to DMT initiation is displayed in
Supplementary Table 6.
Figure 5 (numbers in Supplementary Table 7) shows
that factors for taking at least 1 year until treatment
start were an older age at diagnosis (OR 1.18 (1.09–
1.29) per increase of 5 years) and an earlier year of
diagnosis (1996–2000 1, 2001–2005 0.39 (0.24–
0.64), 2006–2010 0.26 (0.16–0.42), 2011–2015
0.14 (0.09–0.23), 2016 0.20 (0.09–0.40)).
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The sensitivity analysis agreed in the direction of the
effects (Supplementary Tables 7 and 8).
To be consistent, the time to DMT initiation between
the first symptoms and treatment initiation, which
was not considered in the regression analysis is dis-
played in Supplementary Figure 2.
Discussion
Using patient-reported data, we observed that even
in recent time periods a substantial fraction of
PwMS experience an extended time to diagnosis of
at least 2 years (40%). An extended time to diagno-
sis was associated with PPMS, a younger age at the
onset of symptoms, an earlier diagnosis period, not
being diagnosed in a hospital setting, not having
either one of two common first symptoms (gait prob-
lems or paresthesia) and a higher number of uncom-
mon first symptoms.
In a second step, all PwMS with a relapsing-onset
MS and a diagnosis before the year 2017 were scru-
tinised to identify factors associated with an
Table 1. Study populations.
All Time to diagnosis dataset Time to treatment dataset
N per group 1059 990 872
Current type of MS
RRMS 803 (76%) 753 (76%) 737 (85%)
SPMS 147 (14%) 139 (14%) 135 (15%)
PPMS 109 (10%) 98 (10%) 0 (0%)
Women 770 (73%) 719 (73%) 653 (75%)
Age (years) 47 (38–55) 47 (38–55) 46 (37–53)
Age at onset 33 (26–41) 33 (26–41) 32 (25–40)
Age at diagnosis 38 (29–45) 38 (29–45) 36.5 (28–44)
Age at DMT start 38 (29–45) 37 (29–44) 37 (29–44)
Swiss citizen 962 (91%) 896 (91%) 792 (91%)
MS in relatives
Close relatives 80 (8%) 74 (8%) 64 (8%)
Other relatives 124 (12%) 110 (12%) 107 (13%)
DMT (ever) 914 (86%) 861 (87%) 800 (92%)
Diagnosis setting
Neurologist (clinic) 659 (63%) 617 (62%) 553 (64%)
Neurologist (private practice) 371 (35%) 352 (36%) 296 (34%)
General practitioner 22 (2%) 21 (2%) 17 (2%)
Seen a doctor in last 12 months 954 (90%) 894 (90%) 786 (90%)
Diagnosis confirmation received 698 (66%) 652 (66%) 581 (67%)
Column 1 displays the overall dataset, column 2 the dataset for the time to diagnosis analysis and column 3 the time to
treatment dataset. Shown are the absolute numbers or the median for continuous variables. In brackets for factors the
percentage with the specified factor level, for continuous variables the interquartile range.
RRMS: relapsing–remitting multiple sclerosis; SPMS: secondary-progressive multiple sclerosis; PPMS: primary-
progressive multiple sclerosis; DMT: disease-modifying treatment.
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Figure 2. Cumulative incidence of multiple sclerosis
diagnoses curve displaying the time between first symptoms
and diagnosis. The y axis shows the percentage of the whole
sample (n¼996) that is diagnosed within a certain time
frame (years on x axis). The table underneath the graph
displays the number of people who are still ‘at risk’, so not
yet diagnosed, at a given time after the first symptoms. The
dashed line shows the median, which is at 1.1 years.
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extended time to DMT initiation of at least 1 year,
which was observed for 23%. The PwMS with later
or no treatment start tended to be of older age at
diagnosis and were diagnosed in an earlier diagnosis
period.
Overall, the time to diagnosis decreased substantial-
ly over time, which is likely to be an effect of
updated diagnostic guidelines, the availability of
treatment for relapsing MS forms, increased aware-
ness and better communication of the disease.1,12,14
However, additional individual factors could pro-
long the time to diagnosis. The strongest of these
is having PPMS. The immediate explanation for
this finding is that diagnostic guidelines for PPMS
require at least 1 year of disease progression before
the definite diagnosis.1 Especially with first treat-
ments showing positive effects in persons with
PPMS, these guidelines should be critically dis-
cussed.5 Whether additional factors such as different
first symptom profiles for PPMS may have contrib-
uted to extended time to diagnosis is currently not
discernible from these data.
The finding of a greater probability for extended
time to diagnosis in younger persons was shown
Predictors
MS form at onset
Relapsing onset MS
Primary progressive MS
Demographics
Age at onset (+5y)
Male
Diagnostic period
1996 − 2000
2001 − 2005
2006 − 2010
2011 − 2015
2016 − 2017
Diagnostic setting
Neurologist (hospital)
Neurologist (Private Pract.)
General Practitioner
First symptoms (FS)
Gait problems FS
Paresthesia FS
No. of uncommon FS (+1)
OR
1
5.09
0.84
1.18
1
0.83
0.92
0.77
0.55
1
1.54
1.48
0.65
0.72
1.17
0.50 1.0 2.0 4.0 8.0
OR
Figure 3. Extended time between first symptoms and diagnosis (2 years) model displayed in a forest plot. The odds
ratios (ORs) and 95% confidence intervals (CIs) of the individual factors are shown on a log2 scale and the point estimates
are stated at the right side of the plot. Values higher than 1 indicate an association with extended time, below 1 with
shorter time. The reference levels of the factors are (from top to bottom, variable in brackets): type of MS: relapsing-onset
MS (primary progressive MS), sex: female (male), diagnosis period: 1996–2000 (diagnosis period: 2001–2005, 2006–
2010, 2011–2015, 2016–2017), diagnosis setting: neurologist (hospital) (neurologist (private practice), general practi-
tioner) and absence of the stated first symptoms (gait problems first symptom, paresthesia first symptom). diag.: diag-
nosis; pract.: practice; FS: first symptoms. The results are displayed on a log2 scale to give the positive and negative
factors the same weight.
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before and has potential implications for healthcare
and the diagnostic process.14 Because younger per-
sons tend to seek care less frequently, this may con-
tribute to the extended time to diagnosis.24
The effect of diagnoses of neurologists in private
practices being associated with extended times com-
pared to their colleagues in hospitals might be relat-
ed to symptom severity, which was not measured in
this study. We hypothesise that mild cases of MS
more frequently attend private practice neurologists
or general practitioners, whereas persons who are
strongly affected by their first symptoms might
more often seek care in a hospital and emergency
department. If true, then the observed effect may be
more related to disease-specific factors rather than
variations in healthcare setting.
Our findings further point to an important role of
pattern differences in first symptom manifestation.
In particular, we saw that having the common first
MS symptoms gait problems or paresthesia were
associated with shorter time to diagnosis. By con-
trast, an increasing number of uncommon symptoms
led to extended time to diagnosis. We therefore
assume that the awareness of less typical symptoms
can play a key role in promoting quicker MS diag-
nosis. However, as the numbers of PwMS with
specific uncommon first symptoms are rather low
in the SMSR, this will need to be confirmed by fur-
ther studies.
Evidence suggests that a rapid initiation of DMT
after diagnosis positively affects MS disease
course.9–11 Therefore, we examined this aspect of
the disease management. We observed that the
time to DMT initiation evolved in parallel with the
introduction of new diagnostic guidelines, but also
with the availability of novel treatment options. On
an individual level, we observed extended time to
DMT initiation among older persons. It is conceiv-
able that age might influence joint treatment deci-
sions by altering the patients’ preferences (e.g. more
reluctance for initiation at an older age) or a physi-
cian’s perception of the urgency of immediate DMT
start (e.g. because DMT may be more effective at a
younger age).25–29 These aspects clearly warrant fur-
ther investigation.
Due to the observational, self-reported nature of our
study, limitations need to be considered. The date of
the first symptoms is quite likely to be influenced by
recall bias. However, the mostly good agreement in
the sensitivity analyses regarding direction and point
estimates of the effects as well as the good agree-
ment of demographics, disease characteristics and
the age at diagnosis distribution compared to other
studies (except Swiss citizenship), mitigate this con-
cern.19,30–33 In addition, the entire SMSR project
was specifically structured to reduce selection bias
and warrant representativeness (e.g. layer model,
form of participation, communication strategy and
funding body).17,18 The high share of PwMS with
DMT uptake (87–92%) can mainly be explained
by the sample which is only covering diagnoses
after 1995. Considering the entire SMSR database,
the share reduces to 82%, which corresponds well
with other Swiss data and is representative of the
generally high uptake of DMT in Switzerland.32
Moreover, it is likely that our study did not capture
all important influencing factors. In that regard, our
study also reflects current limitations in our under-
standing of the full diagnostic cascade, as well as the
individual characteristics and processes that foster a
quicker diagnosis. For example, we observed that the
diagnostic setting and first symptoms were important
factors in time to diagnosis. However, it remains yet
to uncover whether these factors were exerting their
influence more on the side of patients or the health
system. Furthermore, the effect of the healthy survi-
vor bias on the time trend by missing the group of
rapidly progressing PwMS in the oldest time period
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Figure 4. Cumulative incidence of disease-modifying
treatment (DMT) initiation curve displaying the time
between diagnosis and first DMT initiation. The y axis
names the percentage of the whole sample (n¼872) that is
under DMT within a certain time frame (years on x axis).
The table underneath the graph displays the number of
people who are still ‘at risk’, so not yet treated with DMT,
at a given time after diagnosis. The dashed line shows the
median, which is at 2 months.
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(1996–2000) has to be considered. However, we are
confident that the effect is limited because the study is
structured specifically also to catch the usually under-
represented groups of newly diagnosed or highly dis-
abled PwMS, and the sensitivity analysis on a
restricted dataset (diagnoses 2006–2015) confirmed
that the results are stable (see Supplementary
Appendix and Supplementary Table 5). The
time trend is likely still to exist even if the group of
rapidly progressing PwMS was missing (calculations
in Supplementary material). As a last point, it is
important to note that in general an extended time to
diagnosis may not necessarily be negative, because it
can also be associated with a milder disease course.
We conclude that even in recent periods, substantial
and partially systematic variation regarding time to
diagnosis and time to DMT initiation remains. With
the emerging paradigm of early treatment, the resid-
ual unexplained variation should be monitored
carefully and informed decisions be made about
updating guidelines and raising awareness among
physicians as well as the public.
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